以岭药业(002603) - 2021 Q3 - 季度财报

Revenue and Profit - The company's revenue for Q3 2021 reached ¥2,215,505,872.40, representing a year-on-year increase of 13.01%[4] - Net profit attributable to shareholders was ¥259,549,700.23, a decrease of 14.02% compared to the same period last year[4] - Total operating revenue for the third quarter reached ¥8,111,597,900.32, an increase of 25.8% compared to ¥6,447,356,117.62 in the same period last year[15] - Net profit for the period was ¥1,222,795,539.76, representing a 20.5% increase from ¥1,014,766,683.73 in the previous year[17] - The company reported a total comprehensive income of ¥1,222,929,080.06, compared to ¥1,012,426,540.55 in the previous year, indicating a strong performance[17] Assets and Liabilities - The total assets at the end of the reporting period were ¥12,984,144,152.67, an increase of 12.98% from the end of the previous year[5] - The total assets of the company reached ¥12,984,144,152.67, up from ¥11,492,337,701.65 year-on-year, showing robust growth[15] - The company's total liabilities reached ¥4,031,223,159.40, compared to ¥2,568,984,805.44 in the previous year, reflecting a significant increase[15] - Non-current assets totaled RMB 7.09 billion, an increase from RMB 6.03 billion, indicating a growth of approximately 17.6%[14] Cash Flow - The cash flow from operating activities showed a net outflow of ¥279,291,885.87, a significant decrease of 82.16% compared to the previous year[9] - The total cash inflow from operating activities for the period was CNY 7,359,521,868.91, an increase of 3.69% compared to CNY 7,097,778,177.08 in the previous period[18] - The net cash outflow from operating activities was CNY 279,291,885.87, a significant decrease from CNY 1,565,162,395.79 in the previous period[18] - The cash inflow from investment activities totaled CNY 517,194,920.79, down from CNY 2,332,020,387.34 in the previous period, indicating a decline of approximately 77.8%[19] - The cash inflow from financing activities was CNY 2,399,805,833.33, a substantial increase from CNY 290,328,483.66 in the previous period[19] Research and Development - The company's R&D expenses increased by 37.96% to ¥537,590,964.63, reflecting a focus on innovation[9] - Research and development expenses increased to ¥537,590,964.63, a rise of 37.9% compared to ¥389,666,408.21 in the same period last year[16] Shareholder Information - The basic earnings per share for the period was ¥0.1554, down 14.02% year-on-year[4] - Basic earnings per share increased to ¥0.7324, compared to ¥0.6082 in the same period last year, marking a growth of 20.4%[17] - The company has a total of 1,428,000 shares of stock outstanding[12] Inventory and Receivables - The accounts receivable rose by 56.19% to ¥1,769,260,046.66, indicating increased sales activity[8] - Accounts receivable increased significantly to RMB 1.77 billion, up from RMB 1.13 billion, marking a growth of approximately 56.3%[13] - Inventory levels rose to RMB 1.62 billion, compared to RMB 1.58 billion, reflecting an increase of about 1.5%[13] Expenses - Total operating costs amounted to ¥6,718,420,007.78, up 27.2% from ¥5,281,693,269.35 year-on-year[16] - The company’s sales expenses rose to ¥2,795,771,783.69, an increase of 36.4% from ¥2,048,547,082.19 in the previous year[16] - The cash paid to employees and for employee benefits was CNY 1,577,112,890.60, an increase from CNY 1,003,880,984.45 in the previous period[18] - The cash paid for various taxes was CNY 991,720,675.33, up from CNY 771,677,766.24 in the previous period[18] Financing Activities - The long-term borrowings increased to ¥500,422,500.00, marking a 100% rise as the company sought additional financing[9] - Short-term borrowings increased to RMB 500.42 million from RMB 270.18 million, a rise of about 85.0%[14] - The net cash outflow from financing activities was CNY 281,766,922.15, compared to CNY 21,667,270.81 in the previous period[19]